Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neurology

Daily Life, Caregiving, and Long-Term Planning

At a Glance

CLN13 care should adapt as movement, communication, behavior, and independence change. Home safety, simple routines, early advance care planning, palliative support, and respite services can protect comfort and quality of life for the person and caregiver.

Caring for someone with CLN13 (Kufs disease Type B) is a journey that evolves from supporting independence to providing total comfort [1][2]. Because this condition uniquely affects adults, the experience often mirrors that of early-onset dementia, requiring a combination of practical home safety, behavioral management, and emotional resilience [3][4].

Daily Life and Practical Support

Early in the diagnosis, while the person with CLN13 can actively participate, it is essential to discuss preferences for life-prolonging measures and address practical matters like employment, disability benefits, driving safety, and supported decision-making.

As motor and cognitive abilities change, daily routines must be adapted to keep the home environment safe and supportive [1].

  • Adaptive Environment: Early on, focus on removing fall hazards (like rugs) and installing grab bars [2]. As the disease progresses to ataxia (loss of coordination), you may need to transition to specialized equipment like hospital beds, mechanical lifts for transfers, and wheelchairs [5][6].
  • Communication Adjustments: Speech often becomes more difficult over time [1]. Caregivers can help by using short, simple sentences, providing visual cues, and allowing extra time for the person to process information [7][8].
  • Meaningful Participation: Even in the later stages, engaging the person in “real-life” activities—such as listening to familiar music or simple sensory experiences—can help maintain their quality of life and sense of connection [8][1].

Managing Behavioral Changes

CLN13 often involves “frontal” symptoms, which can lead to behaviors that are difficult for families to manage [9][3].

  • Non-Drug Approaches: Experts recommend non-drug strategies as the first line of defense [10]. This includes maintaining a consistent daily schedule, reducing overstimulation (like loud noises or bright lights), and identifying “triggers” for agitation [11][12].
  • Understanding the Cause: Sudden changes in behavior or increased irritability may be caused by underlying discomfort the person cannot express, such as pain, constipation, an infection, or adverse medication effects [11][13]. These should be ruled out first.
  • Medication Caution: While medications like SSRIs (antidepressants) are sometimes used off-label to help with irritability or repetitive behaviors, psychiatric drugs can have significant side effects in people with NCL [14][9]. Sedating or antipsychotic medications can worsen parkinsonism, increase fall risk, or impair swallowing. Any medication use should be individualized and supervised by a specialist, focused on comfort and relief of distress [9].

Planning for the Late Stages

In the advanced stages of CLN13, a person may enter a state of akinetic mutism, where they are awake but unable to move or speak [15]. This transition requires a shift in care goals from maintaining function to prioritizing comfort [2][16].

  • Early Palliative Care: It is a common misconception that palliative care is only for the very end of life. Instead, it should be integrated early to help manage complex symptoms and guide difficult conversations about future care [17][2].
  • Advance Care Planning: It is essential to discuss preferences for life-prolonging measures (like feeding tubes or ventilators) early. Establishing a healthcare proxy (which varies by legal jurisdiction) ensures that if capacity changes, decisions are guided by the designated proxy following established “best-interest” principles [18][17].
  • Comfort-First Care: Late-stage care focuses on preventing complications. Even when goals become more comfort-focused, physical and occupational therapy may continue to help with proper positioning and preventing joint contractures [16][19]. Care also focuses on managing secretions and ensuring that any pain or seizures are well-controlled [16][19].

Supporting the Caregiver

The emotional and physical toll of caring for a loved one with a rare neurodegenerative disease is immense [20]. Research shows that caregiver burden is highest when behavioral symptoms and physical disability are at their peak [21][22].

  • Respite Care: Seeking “respite”—temporary relief provided by professional home-care workers or residential programs—is not a sign of failure; it is a necessary part of a sustainable care plan [23][24].
  • Support Networks: Joining a support group or connecting with other families through NCL/Batten disease organizations can reduce the isolation that often comes with a rare diagnosis [25][23]. Taking care of your own physical and mental health is the most important thing you can do to ensure you can continue to care for your loved one [25].

Common questions in this guide

How can we make the home safer as CLN13 progresses?
Start by removing fall hazards such as loose rugs and adding grab bars. As coordination and mobility decline, the care team may recommend a wheelchair, hospital bed, or mechanical lift and can help with safe transfers.
What can help with behavior changes in CLN13?
A consistent routine, less noise and bright light, and identifying triggers are often useful first steps. If behavior changes suddenly, ask a clinician to check for pain, constipation, infection, or medication side effects because the person may not be able to communicate discomfort.
Are psychiatric medications safe for people with CLN13?
SSRIs may sometimes be used for irritability or repetitive behaviors, but medication should be individualized and supervised by a clinician familiar with the condition. Sedating or antipsychotic drugs may worsen parkinsonism, increase fall risk, or impair swallowing.
When should palliative care begin for CLN13?
Palliative care can be involved early, not only during the final days of life. It can help manage symptoms, support comfort, and guide conversations about future care while other treatments and therapies continue.
What should advance care planning include for CLN13?
Discuss preferences for treatments such as feeding tubes or ventilators while the person can participate, and document them in an advance directive when appropriate. Naming a healthcare proxy or decision-maker helps ensure choices reflect the person’s known wishes if decision-making capacity changes.
How can caregivers get support while caring for someone with CLN13?
Respite care, including temporary in-home help or residential programs, can give caregivers needed relief and make long-term care more sustainable. Support groups and NCL or Batten disease organizations can connect families with practical resources and emotional support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which non-drug strategies should we implement first to help manage the behavioral or mood changes?
  2. 2.When evaluating a sudden change in behavior, what medical issues (like pain, infection, or medication effects) should we rule out first?
  3. 3.What are the specific risks—such as increased fall risk or swallowing impairment—associated with off-label psychiatric medications?
  4. 4.How can physical and occupational therapy continue to support positioning, comfort, and skin protection as mobility decreases?
  5. 5.Can you help direct us to resources for supported decision-making or establishing a healthcare proxy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Management of CLN1 Disease: International Clinical Consensus.

    Augustine EF, Adams HR, de Los Reyes E, et al.

    Pediatric neurology 2021; (120()):38-51 doi:10.1016/j.pediatrneurol.2021.04.002.

    PMID: 34000449
  2. 2

    Management Strategies for CLN2 Disease.

    Williams RE, Adams HR, Blohm M, et al.

    Pediatric neurology 2017; (69()):102-112 doi:10.1016/j.pediatrneurol.2017.01.034.

    PMID: 28335910
  3. 3

    Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism.

    Gultekin M, Tufekcioglu Z, Baydemir R

    Neurocase 2022; (28(1)):107-109 doi:10.1080/13554794.2022.2038635.

    PMID: 35139754
  4. 4

    Clinical Heterogeneity of Neuronal Ceroid Lipofuscinosis Type 13: A Case Report and Systematic Review of Literature.

    Ghayal NB, Roemer SF, Tipton PW, et al.

    Neurology. Genetics 2025; (11(1)):e200227 doi:10.1212/NXG.0000000000200227.

    PMID: 39720560
  5. 5

    Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.

    Berkovic SF, Oliver KL, Canafoglia L, et al.

    Brain : a journal of neurology 2019; (142(1)):59-69 doi:10.1093/brain/awy297.

    PMID: 30561534
  6. 6

    A novel homozygous CLN6 Tyr142Cys variant in a nonconsanguineous family with Kufs disease.

    Chen B, Liu Y, Cai N, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(9)):4597-4600 doi:10.1007/s10072-024-07579-5.

    PMID: 38771523
  7. 7

    Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease.

    Morison LD, Whiteman IT, Vogel AP, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12838 doi:10.1002/jimd.12838.

    PMID: 39821609
  8. 8

    Overview of advances in educational and social supports for young persons with NCL disorders.

    Elmerskog B, Tøssebro AG, Atkinson R, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2020; (1866(9)):165480 doi:10.1016/j.bbadis.2019.05.016.

    PMID: 31152869
  9. 9

    Psychiatric manifestations in Neuronal ceroid lipofuscinoses.

    Della Vecchia S, Simonati A, Marchese M, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 42298645
  10. 10

    Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress.

    Magierski R, Sobow T, Schwertner E, Religa D

    Frontiers in pharmacology 2020; (11()):1168 doi:10.3389/fphar.2020.01168.

    PMID: 32848775
  11. 11

    Behaviours and psychological symptoms of childhood dementia: two cases of psychosocial interventions.

    Atee M, Whiteman I, Lloyd R, Morris T

    Palliative care and social practice 2024; (18()):26323524241273492 doi:10.1177/26323524241273492.

    PMID: 39247715
  12. 12

    Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.

    Carrarini C, Russo M, Dono F, et al.

    Frontiers in neurology 2021; (12()):644317 doi:10.3389/fneur.2021.644317.

    PMID: 33935943
  13. 13

    Persistent lymphopenia in a Japanese boy with neuronal ceroid lipofuscinosis type 3.

    Kajiwara K, Liang Q, Uchiyama Y, et al.

    European journal of medical genetics 2025; (78()):105058 doi:10.1016/j.ejmg.2025.105058.

    PMID: 41203069
  14. 14

    Behavioral and Cognitive Response to Selective Serotonin Reuptake Inhibitors in Frontotemporal Lobar Degeneration: A Systematic Review and Meta-analysis.

    Nisar M, Abubaker ZJ, Nizam MA, et al.

    Clinical neuropharmacology 2021; (44(5)):175-183 doi:10.1097/WNF.0000000000000469.

    PMID: 34542955
  15. 15

    Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD.

    van der Zee J, Mariën P, Crols R, et al.

    Neurology. Genetics 2016; (2(5)):e102 doi:10.1212/NXG.0000000000000102.

    PMID: 27668283
  16. 16

    Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.

    Mole SE, Schulz A, Badoe E, et al.

    Orphanet journal of rare diseases 2021; (16(1)):185 doi:10.1186/s13023-021-01813-5.

    PMID: 33882967
  17. 17

    Palliative Care in Amyotrophic Lateral Sclerosis.

    Mercadante S, Al-Husinat L

    Journal of pain and symptom management 2023; (66(4)):e485-e499 doi:10.1016/j.jpainsymman.2023.06.029.

    PMID: 37380145
  18. 18

    Ethical Issues in Care and Treatment of Neuronal Ceroid Lipofuscinoses (NCL)-A Personal View.

    Kohlschütter A

    Frontiers in neurology 2021; (12()):692527 doi:10.3389/fneur.2021.692527.

    PMID: 34248829
  19. 19

    Stepwise surgical management of severe dysphagia in multiple system atrophy.

    Ogawa Y, Ueha R, Goto T, et al.

    Auris, nasus, larynx 2026; (53(4)):596-601 doi:10.1016/j.anl.2026.06.005.

    PMID: 42284998
  20. 20

    The Psychiatric Care of Children and Young Adults With Neurodegenerative Diseases.

    Hauptman AJ, Augustine EF, Brown HB

    Journal of the American Academy of Child and Adolescent Psychiatry 2024; (63(12)):1193-1195 doi:10.1016/j.jaac.2024.02.001.

    PMID: 38340894
  21. 21

    Factors impacting caregiver burden in Parkinson's disease: A systematic review and meta-analysis.

    Sin WWF, Chan LML, Ng CTY, et al.

    International journal of nursing studies 2025; (174()):105299 doi:10.1016/j.ijnurstu.2025.105299.

    PMID: 41330214
  22. 22

    Impact of Neuropsychiatric Symptoms on Caregiver Burden of People With Dementia With Lewy Bodies: A Multicentre Prospective Longitudinal Study.

    Hayashi H, Kobayashi R, Shibuya Y, et al.

    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2025; (25(4)):e70051 doi:10.1111/psyg.70051.

    PMID: 40390335
  23. 23

    Comparative efficacy of 11 non-pharmacological interventions on depression, anxiety, quality of life, and caregiver burden for informal caregivers of people with dementia: A systematic review and network meta-analysis.

    Sun Y, Ji M, Leng M, et al.

    International journal of nursing studies 2022; (129()):104204 doi:10.1016/j.ijnurstu.2022.104204.

    PMID: 35247788
  24. 24

    Caregiver burden in atypical dementias: comparing frontotemporal dementia, Creutzfeldt-Jakob disease, and Alzheimer's disease.

    Uflacker A, Edmondson MC, Onyike CU, Appleby BS

    International psychogeriatrics 2016; (28(2)):269-73 doi:10.1017/S1041610215001647.

    PMID: 26435062
  25. 25

    A novel two-day intervention reduces stress in caregivers of persons with dementia.

    Spalding-Wilson KN, Guzmán-Vélez E, Angelica J, et al.

    Alzheimer's & dementia (New York, N. Y.) 2018; (4()):450-460 doi:10.1016/j.trci.2018.08.004.

    PMID: 30258974

This page is for informational purposes only and does not constitute medical advice. A CLN13 care team and qualified legal professional can help tailor medication, palliative care, and advance-planning decisions to your situation.

Get notified when new evidence is published on CLN13 disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.